Header Logo

Connection

Robin Jones to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Antineoplastic Agents.
Robin Jones
Connection Strength
7.463
Antineoplastic Agents
  1. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
    View in: PubMed
    Score: 0.664
  2. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
    View in: PubMed
    Score: 0.621
  3. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
    View in: PubMed
    Score: 0.566
  4. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
    View in: PubMed
    Score: 0.506
  5. Drug repositioning in sarcomas and other rare tumors. EBioMedicine. 2016 Apr; 6:4-5.
    View in: PubMed
    Score: 0.444
  6. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
    View in: PubMed
    Score: 0.427
  7. Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37.
    View in: PubMed
    Score: 0.409
  8. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700.
    View in: PubMed
    Score: 0.400
  9. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7.
    View in: PubMed
    Score: 0.377
  10. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013 Oct; 9(10):1409-11.
    View in: PubMed
    Score: 0.369
  11. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9.
    View in: PubMed
    Score: 0.307
  12. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69.
    View in: PubMed
    Score: 0.229
  13. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18):2853-60.
    View in: PubMed
    Score: 0.217
  14. The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar; 4(2):183-91.
    View in: PubMed
    Score: 0.207
  15. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
    View in: PubMed
    Score: 0.169
  16. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
    View in: PubMed
    Score: 0.161
  17. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol. 2021 Jul; 17(20):2659-2670.
    View in: PubMed
    Score: 0.158
  18. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
    View in: PubMed
    Score: 0.157
  19. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.
    View in: PubMed
    Score: 0.156
  20. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.132
  21. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
    View in: PubMed
    Score: 0.131
  22. Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther. 2017 08; 17(8):717-723.
    View in: PubMed
    Score: 0.121
  23. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810.
    View in: PubMed
    Score: 0.117
  24. Dear John Hunter. BMJ. 2016 12 14; 355:i6515.
    View in: PubMed
    Score: 0.117
  25. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncol. 2017 Jan; 13(2):185-194.
    View in: PubMed
    Score: 0.115
  26. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27.
    View in: PubMed
    Score: 0.096
  27. Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
    View in: PubMed
    Score: 0.040
  28. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213.
    View in: PubMed
    Score: 0.019
  29. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008 Sep; 111(1):27-44.
    View in: PubMed
    Score: 0.015
  30. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol. 2007 Sep; 60(9):1017-23.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.